Immune variants of SARS-CoV-2 could be a significant challenge for developing a pan genotype-specific vaccine

Hum Vaccin Immunother. 2021 Dec 2;17(12):5145-5147. doi: 10.1080/21645515.2021.1997487. Epub 2021 Dec 2.

Abstract

The circulating variants of SARS-CoV-2 pose a threat to the public health response worldwide, especially in the case of developing countries, lacking vaccines and having compromised health-care facilities. This article highlights several recent studies conducted to determine the efficacy of COVID-19 vaccines against variants of concern. These studies comprise clinical trials and neutralization assay-based studies conducted on messenger RNA (mRNA), recombinant, viral vector-based, and inactivated vaccines.

Keywords: COVID-19; genotype; pathogenic; vaccine; variants.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Genotype
  • Humans
  • SARS-CoV-2* / genetics
  • Vaccines, Inactivated

Substances

  • COVID-19 Vaccines
  • Vaccines, Inactivated

Grants and funding

The virus research in our laboratory is supported by the Department of Biotechnology, India [BT/PR24308/NER/95/644/2017 and BT/PR41246/NER/95/1685/2020], and the Department of Health Research, Government of India [NER/71/2020-ECD-I].